#Anaplastic Astrocytoma Market

[jayanthitbrc]

The Business Research Company Unveils Latest 2024 Updates Across Global Market Reports

The global market reports from The Business Research Company have recently been updated to include the latest market sizing data for the year 2024 and projections up to 2033. These refreshed reports present the most up-to-date market sizing information, providing valuable insights into anticipated market sizes and Compound Annual Growth Rates (CAGR) for various industries. The coverage extends to the most dynamically evolving markets across diverse geographies, ensuring a genuinely global perspective.

Key attributes of The Business Research Company's market reports comprise:

Comprehensive Industry Coverage: The reports span over 27 industries, offering in-depth analyses of various sectors.

Extensive Geographical Insight: The reports cover 60+ geographies, providing detailed breakdowns at both regional and country levels.

Holistic Market Analysis: This encompasses market size and growth rates for both historic and forecast periods, detailed market segmentations, insights into competitors, information on mergers and acquisitions, customer data, and analyses of market drivers, trends, and strategies.

View Updated Market Reports For The Forecast Period 2024 – 2033

How Our Reports Can Add Value:

• Global Industry Snapshot: Gain a comprehensive understanding of an industry's entire landscape across various global regions.

• Inflation Impact Evaluation: Assess the potential influence of global inflation on market growth rates.

• Strategic Business Development: Formulate effective business plans backed by localized data and analysis.

• Investment Direction: Identify market segments suitable for investment activities.

• Consumer Behavior Insights: Develop consumer-centric products and services by acquiring insights into consumer behavior.

• Competitive Analysis: Evaluate your business's market position through benchmarking against competitors.

• Precision in Presentations: Enhance the accuracy and relevance of your internal and external presentations using the precise data gathered by our research team.

For enterprises aiming for a competitive edge and strategic advantage, The Business Research Company's recently updated market reports offer priceless insights and actionable intelligence.

Top 7 Updated Market Reports For The Year 2024-2033:

Merkel Cell Carcinoma Treatment Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/merkel-cell-carcinoma-treatment-global-market-report

Schizophrenia Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/schizophrenia-global-market-report

Biometric Payment Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/biometric-payment-global-market-report

Low Melting Fiber Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/low-melting-fiber-global-market-report

Type 1 Diabetes Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/type-1-diabetes-global-market-report

Hyperlipidemia Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Anaplastic Astrocytoma Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The World’s Most Comprehensive Database

The Business Research Company’s flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[technewspoint]

Anaplastic Astrocytoma Market to Witness Growth by 2032, Estimates DelveInsight | Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics

http://dlvr.it/Sp86SW

[jesse-pinkman123]

Astrocytoma is an ailment that creates from astrocytes, star-formed synapses. The infection has been classified into four distinct categories related to the reproduction pace of the cell, and its ability to spread in nearby tissues.

[pranalipawarshinde]

Adult Malignant Glioma Therapeutics Market In-depth Analysis, Business Strategies, and Growth Rate Report by 2026

Adult Malignant Glioma Therapeutics Market – Snapshot

Gliomas account for more than 70% of all primary brain tumors. Glioblastoma is the most common (65%) and most malignant type of glioma. The global adult malignant glioma therapeutics market is characterized by an unmet medical need of improving survival rates. The market is witnessing rapid increase in novel pipeline drug candidates from major as well as emerging market players, supported by government policies to speed up the process of orphan drug approval. Hence, the global adult malignant glioma therapeutics market was valued at US$ 1.3 Bn in 2017 and is projected to expand at a significant CAGR of 9.2% from 2018 to 2026.

Report Overview: https://www.transparencymarketresearch.com/adult-malignant-glioma-therapeutics-market.html

Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline. The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials along with seven years of market exclusivity upon regulatory approval. Moreover, expedited drug discovery process due to advent of high throughput technology and TCGA, and increase in discretionary funding for cancer research have led to the rise in clinical trials against malignant gliomas. However, significant attrition rate in clinical trials and staggeringly high prices of new-generation cancer drugs are the major factors likely to restrain the global adult malignant glioma therapeutics market during the forecast period.

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme, which accounts for 12% to 15% of all intracranial tumors and 50% to 60% of all astrocytic tumors, is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Strong research and development focus of manufacturers, presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing pipeline of innovative novel drugs are attributed to the high growth of the segment. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others. The market is characterized by a unique mix of patent expirations in the chemotherapy segment and rise in new patent approvals for targeted drug therapies. Loss of market exclusivity post patent expiration and reduction in branded drug prices due to competition from generic brands are likely to result in stagnant growth rate of the chemotherapy segment compared to targeted drug therapy. The targeted drug therapy segment is likely to dominate the global adult malignant glioma therapeutics market during the forecast period. This is because the segment comprises a promising pipeline covering diverse novel techniques such as gene therapy, nucleic acid therapies, lytic viruses, stem cells, nanoparticles, and others which are able to cross the blood brain barrier and target novel inhibition points rather than focusing on the inhibition of blood vessel formation.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13211

In terms of region, the global adult malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017, accounting for over 37% share in terms of revenue. Europe was another major market for adult malignant glioma therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe. However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia such as China, Japan, India, and South Korea. The market in Asia Pacific is anticipated to register an above average growth rate during the forecast period owing to relatively high patient population demanding affordable care and improvement in health care infrastructure in rapidly developing countries that aid the early diagnosis of malignant gliomas.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=13211

Major players operating in the global adult malignant glioma therapeutics market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

More Trending Reports by Transparency Market Research:

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

[lookchem-cas]

GMP Grade High Purity Parmaceutical Intermediate API Raw Powder CAS # 83905-01-5 Azithromycin Dihydrate

Azithromycin is a semi-synthetic 15-membered macrolide antibiotic. White or quasi-white crystalline powder; odorless, bitter; slightly damp. This product is soluble in methanol, acetone, chloroform, anhydrous ethanol or dilute hydrochloric acid, and almost insoluble in water.

Basic information: Azithromycin dihydrate 83905-01-5

Product Description

Product Name Azithromycin dihydrate

Synonyms AZITHROMYCIN 2-HYDRATE;1-Oxa-6-azacyclopentadecan-15-one, 13-(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyloxy-, dihydrate, (2R,3S,4R,5R,8;AZITHROMYCINDIHYDRATE(PATENTED-NOSUPPLY);1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, dihydrate, (2R,3S,4R,5R,8R,10R;1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, dihydrate, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-;azithromycin hydrate;Azithromycin (100 mg);(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-Methyl-3-O-Methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptaMethyl-11-[[3,4,6-trideoxy-3-(diMethylaMino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one Dihydrate

CAS 83905-01-5

MF C38H72N2O12

MW 748.99

EINECS 1592732-453-0

Product Categories Macrolides (Antibiotics for Research and Experimental Use);Antibiotics for Research and Experimental Use;Biochemistry;Carbohydrates & Derivatives;Chiral Reagents;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals;SELDANE;Inhibitors

applicationFor respiratory infections, urinary tract infections, skin and soft tissue infections and sexually transmitted diseases

Chemical Properties: Azithromycin dihydrate 117772-70-0

Melting point 126 C

Boiling point 717ºC

alpha D26 -41.4° (c = 1 in CHCl3)

refractive index 47 ° (C=2, EtOH)

RTECS RN6960000

Fp >110°(230°F)

storage temp. -20°C Freezer

solubility Soluble in DMSO at 20mg/ml. Also soluble in chloroform or ethylene chloride

Merck 14,915

Spec. Azithromycin dihydrate 117772-70-0

ITEMSSPECIFICATIONSRESULTS

AppearanceA White or almost white crystalline powder Conforms

SolubilityPractically insoluble in water,freely soluble in

anhydrous ethanol and in methylene chloride Conforms

IdentificationIRConforms

HPLC

CrystallinityMeet the requirements Conforms

PH9.0 ~ 11.09.9

Related substancesDesosaminylazithromycin ≤0.3%DL

N-demethylazithromycin ≤0.7%0.001

Any other single impurity ≤1.0%Conforms

Total impurities≤3.0 %0.015

Residual solventsAcetone ≤0.5%0.003

Loss on drying4.0 % ~ 5.0%0.045

Residue on Ignition≤0.3%0.0004

Melting point50 °C ~ 60 °C50 °C ~ 60 °C

Sulphate ash≤0.1%0.0005

Heavy metals≤ 25 ppmNMT25 ppm

Assay

( calculated on the anhydrous basis)945 ug ~ 103 ug of azithromycin per mg982 ug/ mg

ConclusiionThis product complied with the standard of Enterprise/USP

TestsSpecificationResults

DescriptionWhite or almost white powderComplies

SolubilityPractically insoluble in water, freely soluble in ethanol and in methylene chloride.Complies

Identification

A)IR spectrumConforms to azithromycin RSComplies

B)Rt HPLCConforms to azithromycin RSComplies

Specific rotationBetween -45°and -49°-47.6°

CrystallinityMeets the requirementsMeets the requirements

PHBetween 9.0 and 11.010.32

WaterBetween 4.0%and 5.0%4.7%

Residue on ignitionNot more than 0.3%0.08%

Heavy metalsNot more than 25ppmComplies

AssayNot less than 945μg and more than 1030μg of azithromycin(C38H72N2O12) per mg, calculated on the anhydrous basis967μg per mg

MethanolNot more than 0.3%0.031%

EthanolNot more than 0.05%0.0068%

AcetoneNot more than 0.5%0.1475%

ChloroformNot more than 0.006%0.0037%

Function

Temozolomide is used in the treatment of adults with refractory pleomorphic glioblastoma and anaplastic astrocytoma of chemotherapy drugs.

1.Azithromycin Dihydrate is used for acute throat and tonsillitis which are caused by streptococcus pyogenes, otitis media sinusitis acute bronchitis skin soft tissue infection which are caused by sensitive bacteria.

2.Azithromycin Dihydrate is also used for pneumonia urethritis cervicitis and so on.

Suitable for sensitive caused by the bacterium respiratory tract, skin soft tissue infection caused by the original body of garment of sexually transmitted diseases. For influenzae, pneumococci and mo draw CARDS he caused by bacteria etc of acute brochitis, chronic obstructive pulmonary disease amalgamative infection, pneumonic wait for the efficient above 90%, bacterial remoal reach 85%. For pyogenes, aureaus etc caused furuncle swollen, cellulitis wait, use this product daily 1 times 5 therapy (1.5 g), total cure for 53% ~ 74%, efficient 90%, its curative effect and the benzene thiazole Westwood, erythromycin and cephalosporins ampicillin similar. Single-agent 1g treatment for chlamydial infection, its curative effect with ciprofloxacin or doxycycline grain phase.

Packing

1. Client is first. We are trying to bring maximum profit to our clients and we only share small.

2. Credibility is the most important.

3. Quality control is our life.

4. Great sense of responsibility.

5. We will be responsible for not only our products, our clients, our suppliers, also the society

FAQ

Q1:Can I get a sample?

A:Of course. For most products we can provide you a free sample, while the shipping cost should undertake by your side.

Q2:What's the MOQ?

A: For the high value product, our MOQ starts from 1g and generally starts from 10g.

For other low value product, our MOQ starts from 100g and 1kg.

Q3:Is there any discount?

A:Yes, different quantity has different discount.

Q4: How to confirm the Product Quality before placing orders?

A: By sending you our available free samples.Or if you have special requirement on the goods, we can prepare samples according to your requirement for your confirmation.

Q5:What's your lead time?

A:We can arrange the shipment in 3 working days after receiving your payment, except the customised products.

introduce

1.Azithromycin is used to treat or prevent certain bacterial infections, most often those causing middle ear infection, strep throat , pneumonia, typhoid, and sinusitis

2.It has used primarily to prevent bacterial infections in infants and those with weaker immune system

3.It is also effective aganinst certain sexually transmitted infections , such as non-gonococcal urethritis, chlamydia and cervicitis

4.Azithromycin cin is use for acute pharyngitis , acute tonsillitis caused by Streptococcus pyogenes

5.Azithromycin is used for acute throat and tonsilitis which are caused by streptococcus pyogenes , otitis

6.Azithromycin can treatment of mrdia sinusitis acute bronchitis skin soft tissue infection which are caused by sensitive bacteria

7.Azithromycin is also used for pneumonia urethritis cervicitis and so on.

Company Profile

Arshine Group is composed of 5 subsidiaries, including Arshine Pharmaceutical Co.,Ltd, Arshine Food Additive Co., Ltd, Arshine Animal Healthcare Co., Ltd, Arshine Life Science Co., Ltd and Hangzhou Arshine Branch. Arshine specializes in exporting human and veterinary API, vitamins, amino acids, minerals, food and feed additives and plant extracts etc. Arshine has exported around 2000 products to 90 countries and areas in Europe, Middle East, East Asia and South Asia. Since establishment, Arshine’s annual sales volume has increased from USD 1 million to USD 100 million, growing hundredfold in 10 years. Having established long-term cooperation with more than 800 manufacturers, Arshine is regional sales representative or even exclusive agent for many manufacturers nowadays. To our pride, Arshine ranks among top 10 in all pharmaceutical raw materials export enterprises in China, top 3 in the private exporters.

After-sale Service : Sales: 24hours to reply your E-mail Market information trend share with customers Suggestion for purchase decision Financial: Different payment terms: TT, LC, DP and so on Sino-Sure credit application and market risk control Shipment conditions: Update the whole process from China to destination 10 days by air & 14 days by sea to finish usually Fast custom clearance at destination Doc after shipment date: Same day for air shipment and LCL sea shipment 3 working days for FCL sea shipment 100% clear and perfect docs Reputation: Implementing contract terms strictly Timely solve any discrepancy or goods claims Take our responsibility for loss if it is our liability Others: Assistant: sample working; help you solve the problem in China with others Registration: pr

More details：http://arshine.lookchem.com/

If you have a need, visit our website lookchem.com; register a Lookchem member account and you will have two free opportunities to experience the Lookchem consignment service within the following 12 months. If you have any questions about the content of this notice, please contact the customer feedback, customer service telephone 0571-87562588, thank you!

　　Julie

　　LookChem Service Team

　　Tel:0571-87562563

　　Email: service@lookchem.com

　　Website: www.lookchem.com

[aditi3019]

Glioma Diagnosis and Treatment Market 2020 Global Analysis, Segments, Top Key Players, Industry Growth, Drivers and Recent Trends by Forecast to 2023

Glioma Diagnosis and Treatment Market Analysis  

The global glioma diagnosis and treatment market is projected to have a startling growth at a whopping 10.1% CAGR over the assessment period (2017-2023). Glioma is a kind of tumor that forms in the brain. It is also called primary brain tumor. It is of various types and are entitled resting on the cell type’s origin including glioblastoma, ependymomas, astrocytoma and oligodendrogliomas. Glioma is the most common brain tumor and about 33% brain tumors are gliomas.  

There are many factors that is driving the growth of the glioma diagnosis and treatment market. Some of these factors as per the Market Research Future (MRFR) report include rising prevalence of brain cancer, innovations in brain cancer drugs, introduction of new and effective therapies, rising geriatric population, current unmet needs, increasing awareness among people, access to healthcare facilities, changing financial demands, existence of metastatic tumors and growing medical tourism.  

Glioma Diagnosis and Treatment Market Segmentation  

The market report offers an all-inclusive segmental analysis of the glioma diagnosis and treatment market on the basis of type, diagnosis, treatment, grade, location and end-user.  

Based on type, it is segmented into primary and secondary tumors. Primary tumors are further segmented into mixed gliomas, optic nerve glioma, brainstem glioma, oligodendrogliomas, astrocytoma and ependymomas. The ependymomas is again segmented into anaplastic ependymomas (grade iii), ependymomas (grade ii), myxopapillary ependymomas (grade i) and subependymomas (grade i). The astrocytomas is segmented into benign astrocytomas, glioblastoma multiforme and anaplastic astrocytomas. The optic nerve glioma is segmented into benign optic nerve glioma and malignant optic nerve glioma.  

Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/5877

Based on diagnosis, the glioma diagnosis and treatment market is segmented into Electroencephalography (EEG), molecular testing, biopsy, Positron Emission Tomography (PET) scan, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan and neurological exam.  

Based on treatment, it is segmented into targeted therapy, immunotherapy, radiation therapy, chemotherapy and surgery. Surgery is further segmented into minimally invasive surgery and open surgery.  

Based on grade, the glioma diagnosis and treatment market is segmented into recurrent high-grade gliomas, high-grade gliomas and low-grade gliomas.  

Based on location, it is segmented into infratentorial and supratentorial.  

Based on end-user, the glioma diagnosis and treatment market is segmented into medical research centers, diagnostic centers, hospitals and clinics and others.  

Glioma Diagnosis and Treatment Market Regional Analysis  

Based on region, the glioma diagnosis and treatment market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America will govern the market due to the existence of key players here along with rising prevalence of brain tumor, increasing awareness amid people and rising healthcare expenditure. The glioma diagnosis and treatment market in the APAC region is predicted in being highly lucrative owing to increasing occurrence of brain tumor in China. Besides the expansion of the market is driven by the growing healthcare infrastructure coupled with the existence of the region’s untapped market opportunities. The market here is highly emerging due to the rising presence of manufacturers together with rising market penetration. The glioma diagnosis and treatment market in the Middle East and Africa is expected to have a favorable growth owing to existence of metastatic tumors and growing medical tourism. Moreover, the creation of drug delivery methods, rising awareness of different kinds of brain tumors and combination of modern diagnostic technique are driving the growth of the glioma diagnosis and treatment market.

Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/glioma-diagnosis-treatment-market-5877

Glioma Diagnosis and Treatment Market Key Players  

Leading players profiled in the glioma diagnosis and treatment market include Hitachi Medical Corporation (U.S.), Carestream Health (U.S), AstraZeneca (UK), Amneal Pharmaceuticals. LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Arbor Pharmaceuticals, LLC (U.S.), F. Hoffmann-Le Roche AG (Switerland), Merck & Co., Inc. (U.S.), Toshiba Medical Systems Corporation (Japan), Shimadzu Corporation (Japan), Philips Healthcare (U.S.), Siemens Healthineers (U.S.), GE Healthcare (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Novartis International AG (Switzerland), Taj Pharmaceuticals Limited (India), Pfizer Inc. (U.S.), Sigma-Aldrich Co. (U.S.), Emcure Pharmaceuticals Ltd. (India), and Thermo Fisher Scientific Inc. (U.S.).  

Aug 2018- Researchers at the University of Leeds have discovered a chemical, KHS101 which can help to kill the glioblastoma cells. This research has been published in the Science Translational Medicine which throws light on how this chemical is capable of disrupting the mitochondria’s activity thus shutting off the source of energy of the tumor cells.